The FDA just approved the first-ever PET imaging agent designed specifically for glioma, and it could end one of brain cancer's most frustrating guessing games. Telix Pharmaceuticals' Pixclara doesn't just find tumors; it tells doctors whether what they're seeing is real cancer or just the brain reacting to treatment.
Imagine you're a surgeon about to remove a brain tumor. You've got an MRI, sure, but it's like trying to find a specific person in a stadium using a blurry satellite photo. You can see the crowd, but you can't tell who's who. That's been the reality of glioma surgery and monitoring for decades.
Not anymore. The FDA just approved Pixclara, a PET imaging agent from Australia-based Telix Pharmaceuticals, and it's the first FDA-approved PET drug specifically designed for glioma, the most common malignant primary brain tumor.
Why Glioma Imaging Has Been Stuck in the Dark Ages
Doctors have relied on MRI scans with gadolinium contrast (a dye that highlights abnormalities) to track brain tumors for years. The problem? Gadolinium doesn't actually detect tumor cells. It detects where the blood-brain barrier has broken down, which is a bit like diagnosing a car accident by looking for broken glass on the road. You'll often find some, but it doesn't tell you much about what actually happened.
This becomes a nightmare after treatment. Radiation therapy and chemotherapy can cause the brain to swell and light up on MRI in ways that look exactly like a tumor coming back. Doctors call this "pseudoprogression," and it's one of the most frustrating problems in neuro-oncology. Is the cancer growing again, or is the brain just reacting to treatment? With conventional imaging, the answer is often: we're not sure.
That uncertainty forces doctors into impossible choices. Do you restart aggressive treatment based on a scan that might be lying to you? Or do you wait and risk letting real cancer spread? Neither option feels good.
What Makes Pixclara Different
Pixclara (the generic name is floretyrosine F 18, but let's stick with Pixclara) works on a fundamentally different principle. Instead of looking for leaky blood vessels, it targets amino acid transporters called LAT1 and LAT2 that sit on the surface of glioma cells. Think of these transporters as doorways that tumor cells use to grab nutrients from the bloodstream. Glioma cells have way more of these doorways than normal brain tissue.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
When Pixclara is injected, it travels through the body and gets pulled into cells through those transporters. Because glioma cells are hungry and have more doorways open, they soak up far more of the tracer than surrounding healthy brain. A PET scanner then picks up the signal, creating an image that reflects actual tumor biology rather than just structural damage.
It's the difference between hearing a noise in your house and actually seeing who's there.
The Approval Path Wasn't Exactly Smooth
Telix originally submitted its application and hit a bump, requiring a resubmission of the NDA (New Drug Application). The FDA then accepted the resubmitted filing and granted it priority review, which is reserved for drugs that could offer significant improvements over existing options. Pixclara also snagged both Orphan Drug and Fast Track designations along the way, a regulatory triple play that signaled the FDA recognized a serious unmet need.
The approved indication covers the characterization of recurrent or progressive glioma from treatment-related changes in both adult and pediatric patients. In plain English: it helps doctors figure out whether what they're seeing on a scan is real tumor or just the aftermath of therapy.
Telix assessed the drug in 382 patients with glioma, including 371 adults and 11 pediatric patients who received at least one dose.
Telix: From Startup to Radiopharmaceutical Powerhouse
Telix isn't some scrappy startup rolling the dice on its first product. Founded in Melbourne in 2015 by Dr. Christian Behrenbruch and Dr. Andreas Kluge, the company has quietly built itself into one of the more interesting radiopharmaceutical stories in biotech.
Their commercial breakthrough came with Illuccix, a prostate cancer PET imaging agent that won FDA approval in December 2021. That product turned Telix into a revenue machine: the company posted $803.8 million in revenue for 2025, up 56% year over year. Management is guiding for somewhere between $950 million and $970 million in 2026 revenue.
Pixclara adds a second commercial pillar and pushes Telix deeper into the theranostics space (a strategy that pairs diagnostic imaging with targeted therapy). The company is also developing TLX101-Tx, a therapeutic that uses the same LAT1 targeting mechanism to deliver radioactive iodine-131 directly to glioma cells. Pixclara could eventually serve as a companion diagnostic for that therapy, essentially screening patients to confirm their tumors will respond before treatment starts.
The Bigger Picture for Brain Cancer
Pixclara isn't the first imaging tool to tackle brain tumors. 5-ALA (sold as Gleolan) was approved in 2017 as an optical fluorescence agent that helps surgeons see malignant tissue during surgery. But 5-ALA has limitations: it only works intraoperatively, mainly shows surface-level fluorescence, and can miss infiltrative tumor cells lurking deeper in the brain.
Pixclara fills a different gap entirely. It's a pre-surgical and post-treatment monitoring tool that gives oncologists information they simply couldn't get before. Can you tell if the tumor is truly progressing six months after radiation? That's Pixclara's sweet spot.
For the roughly 100,000 Americans living with glioma at any given time, better imaging could mean fewer unnecessary surgeries, more targeted treatment decisions, and less time spent in diagnostic limbo. It's not a cure, but it's something almost as valuable in oncology: clarity.
What to Watch Next
The commercial rollout will be the real test. Telix already has a distribution network from Illuccix, which should help. But PET imaging requires specialized scanners and radiopharmacy infrastructure, and adoption in neuro-oncology centers will take time.
Keep an eye on the IPAX-BrIGHT trial, Telix's pivotal study of TLX101-Tx in recurrent glioblastoma. If that therapeutic works, Pixclara becomes more than a diagnostic; it becomes the gatekeeper for a treatment pipeline. That's the theranostics playbook, and Telix is running it across multiple tumor types.
For now, though, brain cancer doctors have something they've never had before: a PET scan that actually speaks their language.
Clinical & Regulatory
4 min read
Two Shots a Year. Two Infections Out of 2,180 People.
Gilead's twice-yearly lenacapavir injection produced just 2 HIV infections out of 2,180 people in the PURPOSE 2 trial, crushing daily Truvada by 89%. The science is settled; now comes the hard part.
